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Abstract
Advances in genomics have near-term impact on diagnosis and management of monogenic 
disorders. For common complex diseases, the use of genomic information from multiple loci 
(polygenic model) is generally not useful for diagnosis and individual prediction. In principle, the 
polygenic model could be used along with other risk factors in stratified population screening to 
target interventions. For example, compared to age-based criterion for breast, colorectal, and 
prostate cancer screening, adding polygenic risk and family history holds promise for more 
efficient screening with earlier start and/or increased frequency of screening for segments of the 
population at higher absolute risk than an established screening threshold; and later start and/or 
decreased frequency of screening for segments of the population at lower risks. This approach, 
while promising, faces formidable challenges for building its evidence base and for its 
implementation in practice. Currently, it is unclear whether or not polygenic risk can contribute 
enough discrimination to make stratified screening worthwhile. Empirical data are lacking on 
population-based age-specific absolute risks combining genetic and non-genetic factors, on impact 
of polygenic risk genes on disease natural history, as well as information on comparative balance 
of benefits and harms of stratified interventions. Implementation challenges include difficulties in 
integration of this information in the current health-care system in the United States, the setting of 
appropriate risk thresholds, and ethical, legal, and social issues. In an era of direct-to-consumer 
availability of personal genomic information, the public health and health-care systems need to 
prepare for an evidence-based integration of this information into population screening.
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In this issue of Genetics in Medicine, Chowdhury et al.1 report on the recommendations of 
multidisciplinary expert workshops convened by the Foundation for Genomics and 
Population Health (PHG Foundation) in partnership with the University of Cambridge. 
Participants examined scientific, ethical, and logistical aspects of personalized population 
screening for prostate and breast cancer based on polygenic susceptibility. The authors 
recognized the promise of genetic stratification in population screening for breast and 
prostate cancer and identified key issues that need to be addressed before genetic 
stratification can be implemented in practice, the most important of which is the need to 
recognize the benefits and harms of stratified screening as compared with existing screening 
methods. They also identified several ethical issues such as discrimination of high-risk 
individuals and patient autonomy in relation to genetic testing of minors; the need for 
transparency and clear communication about genetic risk scores; and the need to develop 
new professional competencies and to assess cost effectiveness and acceptability of stratified 
screening programs before implementation.
We commend the authors for the thoughtful analysis and modeling of potential for improved 
effectiveness of screening and for early stakeholder engagement in a rapidly moving field. 
Here, we elaborate on the potential of population screening in an age of genomics and 
personalized medicine. At the outset, we acknowledge that although the promise of 
genomics will be first fulfilled in the diagnosis and management of monogenic disorders, its 
use in population screening for common complex diseases will lag behind due to significant 
evidentiary as well as implementation challenges.
POPULATION SCREENING IN THE AGE OF PERSONALIZATION
The idea of population screening of healthy individuals has been around for more than 100 
years and has captured the interest of health-care providers, public health professionals, and 
the general public.2 The main purpose of screening is early detection of asymptomatic 
disease or risk assessment for future disease to improve health outcomes. Scientific and 
logistical principles for screening have been discussed by many organizations, most notably 
Wilson and Junger’s 1968 World Health Organization criteria,3 and have evolved over 
time.2 These principles ensure that the benefits of screening programs outweigh potential 
harms. Generally, people tend to overestimate the positive health impact of screening and 
underestimate the potential for harmful effects such as overdiagnosis, inappropriate 
interventions, and anxiety.4 For many years, the US Preventive Services Task Force 
(USPSTF) has regularly conducted systematic reviews of benefits and harms for screening 
programs and developed evidence-based recommendations.5
One of the criticisms leveled against evidence-based population screening is that guidelines 
typically apply to the “average” person in the population and may not be relevant to 
subgroups of the population with differing levels of risk, a fundamental tenet of personalized 
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medicine that is largely driven by advances in genomics.6 For example, in breast cancer 
screening, the USPSTF currently recommends biennial screening mammography for women 
aged 50–74 years.7 However, they do acknowledge that the decision to start regular 
screening mammography before the age of 50 years should be an individual one and should 
take patient context into account, including the patient’s other risk factors and values 
regarding specific benefits and harms. This second recommendation reflects the continued 
debate and uncertainty about the value of breast cancer screening in those younger than 50.8 
For prostate cancer, the USPSTF currently recommends against prostate-specific antigen 
screening in men, as a result of a recent systematic reviews of the balance of benefits and 
harms from such screening.9 The debate over prostate cancer screening in the United States 
has been ongoing for years, and the USPSTF recently concluded that the harms outweigh 
any potential benefits of screening for the majority of men.
GENETICS AND POPULATION SCREENING
Could advances in genomics improve the benefits of population screening beyond “average 
risk” screening guidelines? Rapid progress in genomics is unraveling the genetic 
architecture of human disease.10 The applications of genetic discoveries for >2,500 
monogenic diseases with available tests (such as Huntington disease and cystic fibrosis) 
have been relatively straightforward in terms of diagnosis and counseling of patients and 
relatives.11 Advances in whole-genome sequencing are promising near-term applications 
into the work-up of rare conditions strongly suspected to have a genetic basis.12 Already, a 
few applications of next-generation sequencing have been used in practice, and more is to 
come as the price of this technology declines and its analytic performance is enhanced.13
For almost 50 years, newborn screening has been the poster child of population screening as 
more and more countries around the world screen all newborns for an increasing number of 
rare genetic and metabolic conditions in order to prevent early death or disability.14 
Screening tests are known to have high false-positive rates and thus are poorly predictive of 
disease for any given individual in the population. Screening tests are usually followed by 
more definitive diagnostic tests. In these settings, the emphasis of population screening is to 
find all cases of disease in the population (maximizing sensitivity). Individuals who are 
labeled as positive as a result of screening often undergo follow-up procedures, tests, or 
interventions and may experience anxiety. As a result, recent reviews of population- based 
screening have emphasized the need for a systematic evidence-based approach to assess 
both the benefits and harms of population screening to individuals and populations.15
In addition to newborn screening, a few selected monogenic disorders provide a window on 
personalization of screening recommendations in adults. For example, in the case of 
hereditary breast and ovarian cancer, the USPSTF currently recommends that all women 
with strong family history for breast and ovarian cancer be offered genetic counseling and 
evaluation for BRCA testing to reduce morbidity and mortality from breast and ovarian 
cancer.16 Generally, BRCA genes account for a small percent of breast cancer in the 
population but have a much higher absolute risk of disease among affected individuals. 
Similarly, the USPSTF recommends that colorectal cancer (CRC) screening is begun at the 
age of 50 years for people at an average risk in the population.17 However, for about 1 in 
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400 people, who have a highly penetrant single-gene disorder, Lynch syndrome (which 
accounts for 3–5% of all CRC), clinical guidelines recommend that CRC screening be 
started in patients in the twenties.18 The Evaluation of Genomic Applications in Practice and 
Prevention working group, an evidence panel sponsored by the Centers for Disease Control 
and Prevention that was modeled after the USPSTF in genomic medicine, recently 
recommended that all newly diagnosed cases of CRC in the population be tested for Lynch 
syndrome, cascade testing be done for their relatives to make early diagnosis of Lynch 
syndrome, and earlier and more frequent CRC screening and surveillance be instituted.19
DOES POLYGENIC INHERITANCE HAVE A ROLE IN POPULATION 
SCREENING?
The contribution of genetics to most common diseases has long been captured under the 
rubric of polygenic inheritance,20 in which additive effects of numerous genes along with 
environmental determinants create a normal distribution of disease risk in the population. 
Until recently, the polygenic contribution to disease remained elusive and could only be 
described through metrics of heritability obtained from twin and family studies.21 A flurry 
of recent genome-wide association studies has changed the landscape, however, with 
hundreds of genetic variants uncovered for a wide variety of diseases.22
To explore the clinical validity and utility of polygenic information, studies have been 
conducted for type 2 diabetes, coronary heart disease, breast cancer, prostate cancer, 
multiple sclerosis, and others.23–30 Collectively, analyses show that the contribution of a 
combination of multiple alleles at multiple loci will be limited in predicting disease for any 
given individual. This is because the effect of individual variants on disease risk is quite 
modest (usually 5–20% increase in risk; odds ratios of 1.05–1.20), and thus most individuals 
are at slightly increased or slightly decreased risk as compared with the average risk of the 
underlying population. Even for people at the extremes of the distribution, disease risk is 
moderately increased, and very few people belong to the extremes of the distribution. For 
example, Pashayan and Pharoah31 show that for the 30 prostate cancer risk alleles, the 5% of 
the population at highest risk will have a twofold relative risk as compared with the 
population average. Furthermore, many of these studies show that adding polygenic 
information to risk-prediction models, when available, provide no or little additional 
discrimination (as reflected in analyses of the area under the curve) to current risk-prediction 
models based on traditional risk factors such as age, body mass index, and lipid levels. As 
discussed by Chowdhury et al.,1 a risk-stratification model must have adequate 
discrimination and calibration, and it should produce several strata of the population for 
which different management strategies are needed to improve population health outcomes. 
The clinical utility of testing for polygenic inheritance is established if testing provides 
better predictive ability than existing strategies, or comparable predictive ability at lower 
costs.
From what we know today, these conditions are largely unmet for most common human 
diseases. In fact, for most diseases, family history remains the most consistent risk factor, 
even after considering available genetic variants, perhaps reflecting unmeasured genes, 
shared environments, or complex gene–environment interactions.32 Collectively, the 
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findings from genome-wide association studies do not explain the known familial clustering 
of common diseases,33 which is also likely due to shared environmental factors and complex 
gene–environment interactions. Thus, risk profiles obtained from known genetic variants do 
not provide sufficient discrimination to warrant integration of polygenic inheritance in 
individual disease prediction. As Wald and Morris34 comment in a recent paper, “there is 
little scope for genetic testing in the prediction of common disease; it is an area where hope 
unfortunately trumps the negative evidence. Risk factors that can make a significant 
contribution to the burden of a disease are, within a population, usually too weakly 
associated with the disease they cause to be useful predictors of who will become affected. 
Common diseases occur commonly, and it is usually not useful to screen for something that 
is common. In such circumstances, a population-wide approach is needed that is simple, 
effective, and safe. Screening based on age alone may be enough in these circumstances; the 
use of more complex assessments can be a distraction and unfruitful.”34
Given that polygenic inheritance leads to low individual risk prediction and personalized 
interventions, could it still be useful as a risk stratifier in population screening to target 
population subgroups at high risk of disease or even find subgroups at low risk of disease to 
avoid testing and other interventions that carry both potential benefits and harms? Pashayan 
and Pharoah31 have previously pointed to the potential for clinical utility of polygenic risk 
stratification in population-based screening for breast cancer. In the United Kingdom, the 
National Health Service offers screening to women between the ages of 47 and 69 years 
(47–69 from 2012). This age-based criterion for eligibility to screening is suboptimal 
because many women younger than 50 years will develop cancer and most women older 
than 69 years will not develop breast cancer. However, identical absolute risk thresholds for 
screening could also be determined by a combination of age and polygenic risk profile. 
Under this schema, they compared breast cancer screening in which women are screened 
from the age of 47 (10-year absolute risk of ≥2%), and genetically stratified screening in 
which women are screened at 2.5% absolute risk calculated on the basis of age and 
polygenic risk. Using an age-based criterion alone, 65% of women would be eligible for 
screening, with 85% of cases detected in the screened population. Using a stratified 
screening strategy, 50% of women would be screened, with 73% of cases detected. Thus, the 
number of women eligible for screening would be 24% fewer at a cost of 14% fewer screen-
detectable cases.31 Assuming all possible genetic susceptibility variants for breast cancer are 
known, they found that 28% would be screened and 76% of the cases would occur in the 
screened population. As compared with screening from age 47, 57% fewer women would be 
screened at a cost of detecting 10% fewer cases. Thus, “a reduction in the number of 
individuals offered screening would also reduce the harms associated with screening, 
including a reduction in overdiagnosis and a reduction in false-positives with all the 
consequences that these adverse outcomes entail.”31 From our perspective, for a not-too-
realistic scenario, these numbers provide a theoretical upper bound for the role of polygenes 
in breast cancer as the remaining “missing heritability” may involve many rare genetic 
variations, complex gene–environment interactions, or posttranslational alterations such as 
epigenetics.
Nevertheless, this kind of reasoning, if supported by empirical data, could have a major 
influence on the way we think about population screening. For example, it would imply that 
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some women currently getting screening would be missed, even if at better “efficiency” of 
the screening program. As discussed by Chowdhury et al.,1 one option is to retain current 
age categories and add younger groups with higher risk (which is something we currently do 
in the case of the very high risk associated with BRCA mutations). Another option is to use 
“absolute risk” as the main criterion for screening and start to exclude older women who are 
getting screened now. These issues are important when considering the overall impact of 
breast cancer screening. A recent analysis of US breast cancer surveillance data from 1976 
to 2008 showed that despite substantial increases in the number of cases of early-stage 
breast cancer, screening has only marginally reduced the rate of advanced cancer. This 
suggests that that there is substantial overdiagnosis, and that screening is having, at best, 
only a small effect on the rate of death from breast cancer.35 Thus, it will be even more 
important for any stratified or personalized screening regimen that involves genetic factors 
to detect early cases of breast cancer that will benefit from screening (i.e., they have 
different natural history and are treatable), rather than purely using numerical thresholds of 
absolute risks. Currently, we have limited information on the impact of polygenic risk on 
breast cancer natural history.
Using modeling of available genetic variants in prostate cancer, the same authors have also 
explored genetic risk stratification in prostate cancer screening.36 They found that a 
stratified approach for screening could halve the number of screenings required and could 
reduce the overall costs associated with screening. However, even if we get a more complete 
picture of the polygenic inheritance in prostate cancer, current evidence in the United States 
shows more harms than benefits for prostatespecific antigen screening,9 especially for high-
risk groups.37 This suggests that in prostate cancer, using polygenic profiles for risk 
assessment may not be as fruitful as for breast cancer. This is reflected in the recent 
Evaluation of Genomic Applications in Practice and Prevention–sponsored evidence review 
on the use of single-nucleotide polymorphism profiles in prostate cancer risk assessment.38 
Again, issues of absolute risk thresholds for screening in relation to overdiagnosis and 
natural history apply to prostate cancer screening, similar to breast cancer screening as 
discussed above.
A third example, largely unexplored by the authors, is CRC screening. The USPSTF 
currently recommends screening for CRC using fecal occult blood testing, sigmoidoscopy, 
or colonoscopy in adults, beginning at the age of 50 years and continuing until 75 years.17 
CRC screening, as with any screening, is most effective when it is applied to a large 
percentage of eligible people and utilized appropriately. In 2010, a National Institutes of 
Health state-of-the-science conference analyzed suboptimal national screening rates for 
CRC, identified the barriers to screening, and proposed solutions to increase screening 
rates.39 The independent panel found that despite substantial progress toward higher CRC 
screening rates nationally, screening rates fall short of desirable levels. Targeted initiatives 
to improve screening rates and reduce disparities in underscreened communities and 
population subgroups could further reduce CRC morbidity and mortality. Could targeting on 
the basis of genetic susceptibility improve the overall effectiveness of CRC screening? As 
with breast cancer, an increasing number of genetic variants with weak additive effects have 
been associated with an increased risk of CRC.40 This raises the possibility that some 
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population stratification of risk for CRC, on the basis of polygenic inheritance, can be 
undertaken in conjunction with age and family history to improve the uptake and efficiency 
of current screening. It has long been known that individuals with first-degree relatives with 
CRC have an almost twofold increase in the risk of CRC.41 For these individuals, their 
absolute risk of CRC is almost the same at 40 years as compared with an “average” 50-year-
old person drawn from the population.42 Recently, Wilschut et al.43 evaluated how many 
screenings should be recommended to individuals with various degrees of family history. On 
the basis of population data, they conducted modeling to estimate the impact of stratified 
CRC screening strategies varying by age at which screening is started and stopped in 
addition to the screening interval. They found that optimal screening strategies varied 
considerably with the number of affected first-degree relatives and their age of diagnosis. 
Shorter screening intervals than the currently recommended 5 years were found to be 
appropriate for the highest-risk group.43 With additional information, one would be able to 
do the same type of calculations that Pashayan and Pharoah did for breast cancer screening. 
Nonetheless, we could envision that in the case of CRC screening, polygenic inheritance 
will also provide a fuller distribution of CRC risk than family history alone, which includes 
people at the lower end of risks, who may or may not benefit from the recommended start of 
CRC screening at 50 years of age if their absolute risks are much lower than the population 
average, or may not need the same screening interval (10 years).
THE BOTTOM LINE: NEED FOR EMPIRICAL EVIDENCE
The use of polygenic risk information in population screening is an intriguing idea that 
needs to be further explored using empirical evidence, in addition to modeling. As discussed 
by Chowdhury et al.,1 and expanded below, many questions need to be answered before 
polygenic inheritance can be integrated into a population screening paradigm. First, the 
analytic validity of the polygenic test is an essential prerequisite for its use in practice for 
any clinical indication. Currently, the analytic performance of whole-genome analysis is 
rapidly improving with high sensitivity and specificity, but a relatively small error rate can 
translate into millions of false calls across the genome.44 Applications of polygenes will still 
have to wait for more reliable technology with quality control and assurance. Second, 
credible epidemiological data should be available on genetic and nongenetic risk factors in 
the population to be tested. This is where the information is so much in flux right now, and 
much of it is derived from case–control studies45 in which potential biases and limitations 
can interfere with inference and interpretation. These include the lack of representation of 
the spectrum of disease in cases, the potential nonrepresentativeness of controls, issues in 
confounding, selection bias and population stratification, and lack of consideration and/or 
accurate measurement of important non-genetic risk factors for the disease in question.46 
The lack of reliable epidemiological information is compounded by the inability of current 
studies to address all common and rare genetic variations in the genome, the so-called 
missing heritability. Integration of whole-genome sequencing technology into well-powered 
large-scale population cohort studies will help fill the knowledge gaps in the next decade.47
Third, the computation of an overall age-specific absolute risk of disease conferred by 
multiple genetic variants will remain a major challenge for the foreseeable future.47 The 
current approach is to multiply the odds ratios associated with each risk variant to arrive at a 
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composite risk score. This method of integration assumes statistical independence between 
risk variants and ignores the potential for undetected gene–environment interactions that 
alter risk, a scenario unlikely to endure as the number of discovered variants increases, 
potentially leading to overestimation of disease risk. One common approach is to simply 
sum up the number of well-replicated risk alleles for a specific disease that any given 
individual carries. Integrating risk conferred by multiple variants and nongenetic factors is 
probably the most daunting challenge in this regard. Due to the complex genetic architecture 
of many common diseases, it will be difficult to identify the dependencies and interactions 
among genetic and nongenetic risk factors. Given the large role of environmental factors in 
the development of common diseases, analytic integration of genetic and nongenetic factors 
to disease risk is crucial.48
Fourth, the impact of polygenic inheritance on the natural history of the disease needs to be 
understood. One of the major challenges of screening has been the need to identify 
individuals who will actually benefit from early detection: those who have aggressive forms 
of the disease that will need earlier interventions as opposed to indolent cases that could be 
diagnosed later. At this point, it is unclear whether polygenic risk stratification will aid in 
the differentiation between life-threatening cancers and mild, chronic forms (e.g., prostate 
cancer;49 rapid progression of polyps in CRC50).
Fifth, the balance of benefits and harms of available interventions, including costs, to 
individuals and populations should be carefully studied when polygenic testing is considered 
to stratify risk. In this context, the ideal designs for evaluation are randomized clinical trials 
comparing the outcomes of risk stratification with current (nonstratified) practice.51 A 
crucial question to address is whether the interventions work the same way or have the same 
effects on disease natural history across the polygenic risk distribution. In this situation, 
randomized trials are quite expensive, require large sample sizes, and take long periods to 
implement. Observational, quasiexperimental, and comparative effectiveness studies have 
been recently proposed as additional tools in the evaluation of population stratification.52 
The use of decision analysis and economic modeling can provide valuable additional 
information to inform decisions about pilot implementation studies. Such studies can collect 
real-world data on benefits, harms, and costs.53 Further methodological work is clearly 
needed in this field.
Sixth, it is important to consider the acceptability of this approach within the larger societal 
and policy issues54 in the United States. In a time of limited health-care resources in which 
there are major disparities in access to recommended preventive services to the population, 
would a polygenic risk stratification be viewed more or less favorably than other forms of 
stratification, for instance by age, income, or other population subgroups that are known to 
have differential rates of morbidity and mortality from the disease in question, as well as 
access to available interventions? Because the intervention has both clinical benefits to 
persons who are identified as positive through the screening and potential significant harms, 
such as anxiety, unnecessary health-care costs, and potentially harmful interventions (e.g., 
prostate cancer), it may make more sense to do risk stratification to maximize benefits and 
minimize harms. However, genetics is only one form of stratification, and we should not 
abide by the notion of “genetic exceptionalism” in this regard.55 We need to evaluate 
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whether the polygenic information combined with other nongenetic risk factors can provide 
a rationale for a stratified approach to population screening as compared with current 
approaches that are geared to the “average” population. Certainly, stratification based on age 
(e.g., in cancer screening), although not a perfect discriminator, is much cheaper and easier 
to implement than stratification on the basis of whole-genome sequencing. Adding a few 
more variables could provide additional discrimination and may be closer to the clinical 
endpoints (e.g., body mass index, fasting glucose level in the prediction of type 2 diabetes). 
Nevertheless, one advantage for polygenic risks is that we can obtain this information at any 
point in life, predating by years or even decades the presence or absence of the 
endophenotypes (e.g., lipid levels), which occur closer to the onset of disease. If there is a 
rationale and scientific evidence that earlier intervention will make a difference on health 
outcomes, this will make a stronger case for using polygenic information to stratify 
population risks. Perhaps the biggest potential use of polygenic inheritance in population 
stratification may be the identification of low-risk groups that may require no or less 
screening. The symmetry of the polygenic curve allows risk stratification of additive genetic 
factors at both ends of the distribution, whereas most single-gene disorders like BRCA and 
Lynch syndrome give us only the upper end of risk, in which more or earlier interventions 
are needed. However, the acceptability of doing less screening for some segments of the 
population is uncertain and will need to be carefully explored.
HOW DOES POLYGENIC INHERITANCE FIT WITH DIRECT-TO-CONSUMER 
PERSONAL GENOMIC TESTS?
Finally, although our focus here is on “population utility” in the use of polygenic risk 
information, there is an emerging literature describing and quantifying the concept of 
“personal utility” of genomic risk information.56 This interest has evolved primarily as a 
result of the availability of personal genomic tests that are sold directly to consumers with or 
without the involvement of health-care providers.57 Information thus far available from 
personal genomic tests essentially derives from polygenic risk information obtained from 
genome-wide association studies. Varying opinions exist within the scientific community 
and the general public about the inherent value of genetic information for different 
purposes.58 We do not address these issues here and refer readers to previous publications 
on this topic including the need for a multidisciplinary research agenda, with a strong 
emphasis on behavioral, social, and communication sciences.59 It is crucial to engage 
consumers in shared decision making about the use of polygenic risk information for 
improving health. With dramatic improvements in genomic-sequencing technologies and 
expected drop in prices in the next few years, it is imperative for appropriate research to be 
conducted to allow scientific inferences on the value of polygenic risk information to 
individuals and populations before widespread integration of such information in clinical 
practice.
CONCLUDING REMARKS
Population screening for rare genetic diseases with high penetrance will continue to be a 
mainstay for genetic screening. However, technological developments will drive the interest 
in using polygenic inheritance as a risk stratifier in population screening for common 
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disease. As discussed in this article and by Chowdhury et al.,1 this is an intriguing concept 
that has many evidentiary and implementation challenges. The incremental value of using 
polygenic inheritance in population screening, as compared with other forms of 
stratification, will have to be rigorously explored. In the meantime, full engagement of the 
scientific community, clinical and public health practice, consumers, and policy makers is 
required to prepare for the evidence-based integration of genomic information into health 
care and public health practice.
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